Affiliation:
1. Epitracker Inc., San Diego, CA 92106, USA
2. Seraphina Therapeutics, Inc., San Diego, CA 92106, USA
3. Translational Genomics Research Institute (TGen), City of Hope, Phoenix, AZ 85004, USA
Abstract
Pentadecanoic acid (C15:0) is an essential odd-chain saturated fatty acid with broad activities relevant to protecting cardiometabolic, immune, and liver health. C15:0 activates AMPK and inhibits mTOR, both of which are core components of the human longevity pathway. To assess the potential for C15:0 to enhance processes associated with longevity and healthspan, we used human cell-based molecular phenotyping assays to compare C15:0 with three longevity-enhancing candidates: acarbose, metformin, and rapamycin. C15:0 (n = 36 activities in 10 of 12 cell systems) and rapamycin (n = 32 activities in 12 of 12 systems) had the most clinically relevant, dose-dependent activities. At their optimal doses, C15:0 (17 µM) and rapamycin (9 µM) shared 24 activities across 10 cell systems, including anti-inflammatory (e.g., lowered MCP-1, TNFα, IL-10, IL-17A/F), antifibrotic, and anticancer activities, which are further supported by previously published in vitro and in vivo studies. Paired with prior demonstrated abilities for C15:0 to target longevity pathways, hallmarks of aging, aging rate biomarkers, and core components of type 2 diabetes, heart disease, cancer, and nonalcoholic fatty liver disease, our results support C15:0 as an essential nutrient with activities equivalent to, or surpassing, leading longevity-enhancing candidate compounds.
Subject
Food Science,Nutrition and Dietetics
Reference111 articles.
1. Odd chain fatty acids and odd chain phenolic lipids (alkylresorcinols) are essential for diet;Dornan;J. Am. Chem. Soc.,2021
2. Efficacy of dietary odd-chain saturated fatty acid pentadecanoic acid parallels broad associated health benefits in humans: Could it be essential?;Lumpkin;Sci. Rep.,2020
3. Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: The EPIC-InterAct case-cohort study;Forouhi;Lancet Diab. Endocrinol.,2014
4. Circulating saturated fatty acids and incident type 2 diabetes: A systematic review and meta-analysis;Huang;Nutrients,2019
5. Imamura, F., Fretts, A., Marklund, M., Korat, A.V.A., Yang, W., Lankinen, M., Qureshi, W., Helmer, C., Chen, T., and Wong, K. (2018). Fatty acid biomarkers of dairy fat consumption and incidence of type 2 diabetes: A pooled analysis of prospective cohort studies. PLoS Med., 15.